RESUMEN
CONTEXTO CLÍNICO O câncer ginecológico afeta diretamente a fertilidade, pois o tratamento consiste na remoção cirúrgica do sistema reprodutor e/ou na sua exposição a agentes gonadotóxicos. Entretanto, pacientes em estádios iniciais e que estejam dentro de critérios estabelecidos podem ser tratadas com cirurgias conservadoras da fertilidade, com resultados oncológicos equivalentes aos dos tratamentos tradicionais. As técnicas de preservação da fertilidade, como criopreservação de oócitos, embriões e tecido ovariano, também podem ser oferecidas em algumas situações. A American Society of Clinical Oncology (ASCO) publicou recomendações sobre a preservação de fertilidade, com o objetivo de aumentar a conscientização sobre o tema, e, juntamente com a American Society for Reproductive Medicine (ASRM), recomenda que pacientes em idade fértil com câncer passem por aconselhamento reprodutivo. Essas pacientes apresentam menores taxas de arrependimento, mesmo quando optam por desistir do tratamento conservador. O interesse na preservação da fertilidade aumentou nas últimas décadas, tanto pelo fato de as mulheres postergarem a gestação como pelo aumento da incidência de câncer em jovens. A taxa de incidência de todos os cânceres aumentou 29% entre 1973 e 2015 em adolescentes e adultos jovens de ambos os sexos. O câncer de colo uterino, em mulheres de 20-29 anos, aumentou anualmente em uma média de 10,3% entre 2000 e 2009. A omissão em orientar pacientes com câncer sobre as possibilidades de preservação da fertilidade pode gerar questionamentos futuros; em alguns países. isso já se configura má prática médica.
Asunto(s)
Humanos , Femenino , Preservación de la Fertilidad/métodos , Neoplasias de los Genitales Femeninos , Trimestres del Embarazo , Técnicas Reproductivas Asistidas , Derechos Sexuales y Reproductivos/ética , Tratamiento Conservador/métodos , Neoplasias de los Genitales Femeninos/diagnóstico por imagen , Hormonas/uso terapéuticoAsunto(s)
Humanos , Femenino , Oocitos , Criopreservación , Preservación de la Fertilidad/métodos , Embrión de MamíferosRESUMEN
Hemorragia pós-parto é a maior causa de histerectomia periparto. Esta revisão descreve e ilustra as técnicas de ligaduras vasculares utilizadas no tratamento cirúrgico da hemorragia pós-parto. São apresentados os detalhes técnicos da ligadura das artérias uterinas, da ligadura das conexões útero-ovarianas, da ligadura tríplice de Tsirulnikov, das ligaduras sequenciais de AbdRabbo e de Morel e da ligadura das artérias ilíacas internas. Também são revistos os fatores que dificultam o sucesso dessas técnicas. As ligaduras vasculares são estratégias eficientes para o controle hemorrágico durante cesarianas e devem integrar o conjunto de técnicas que preservam o útero no tratamento da hemorragia pós-parto.(AU)
Postpartum hemorrhage is the major cause of peripartum hysterectomy. This review describes and illustrates the techniques of vascular ligations used in the surgical treatment of postpartum hemorrhage. The technical details of the uterine arteries ligation, of the ligation of the utero-ovarian connections, of the Tsirulnikov triple ligation, of the AbdRabbo and Morel sequential ligations and of the internal iliac arteries ligation are presented. The factors that hinder the success of these techniques also are reviewed. Vascular ligations are efficient strategies for hemorrhagic control during cesarean sections and should integrate the set of techniques that preserve the uterus in the treatment of postpartum hemorrhage.(AU)
Asunto(s)
Humanos , Femenino , Embarazo , Arteria Uterina/cirugía , Hemorragia Posparto/cirugía , Ligadura/métodos , Bases de Datos Bibliográficas , Preservación de la Fertilidad/métodos , Hemorragia Posparto/mortalidadRESUMEN
La sobrevida de pacientes con cáncer ha mejorado con el tiempo, especialmente en pacientes en edad fértil. La criopreservación de los ovocitos a través de la estimulación ovárica controlada (EOC) es la técnica más frecuente de preservación de la fertilidad. El objetivo del presente estudio es realizar un análisis descriptivo de los ciclos de pacientes que, previo al tratamiento de cáncer, realizaron un tratamiento de preservación de fertilidad. Se analizaron datos demográficos como edad, diagnóstico de ingreso y resultados clínicos, tales como tipo de protocolo de estimulación utilizado, número de ovocitos obtenidos, duración de la estimulación y momento de inicio en el ciclo. Resultados: La edad promedio fue 28.9 años. La duración media de la estimulación fue de 12 días, con un promedio de ovocitos obtenidos en total de 12. Se utilizaron 2 protocolos de estimulación ovárica, obteniendo mejores resultados con el esquema de antagonistas de GnRH asociado a letrozole y doble gatillante. Respecto al momento del ciclo en que se inició la estimulación ovárica, no hubo diferencias. Conclusiones: Es posible realizar preservación de la fertilidad previo a un tratamiento oncológico con buenos resultados en pacientes jóvenes, por lo que sugerimos realizarlo en todos los pacientes con diagnóstico oncológico antes el tratamiento del cáncer. Es recomendable comenzar la estimulación ovárica en cualquier fase del ciclo ya que se obtienen los mismos resultados y permite un pronto inicio de la terapia oncológica.
Survival of patients with cancer has been improving over time, especially in young patient with fertility intention. Cryopreservation of oocytes through controlled ovarian stimulation (EOC) is the most frequent technique of fertility preservation. We analyzed the data obtained from oncological patients who attended IVI Chile between January 2008 and May 2017 in search of fertility preservation. Demographic data were obtained: age, diagnosis of admission, type of stimulation protocol used, number of oocytes obtained, duration of stimulation and pregnancy rate. Results: The average age: 28,9 years; average duration of stimulation:12 days. Number of oocytes obtained in total: 12. Two ovarian stimulation protocols were used. The one with the best results was the protocol with GnRH antagonists associated with letrozole and double triggering. Regarding the moment of the cycle where to start ovarian stimulation, there were no differences. Conclusions: It is possible to carry out a fertility preservation treatment prior to an oncological treatment with good results in young patients, so we suggest the preservation of fertility in all patients with an oncological diagnosis before oncological treatment. It is recommended to start ovarian stimulation at any phase of the cycle since the same results are obtained.
Asunto(s)
Humanos , Femenino , Adolescente , Adulto , Adulto Joven , Oocitos/fisiología , Inducción de la Ovulación/métodos , Vitrificación , Preservación de la Fertilidad/métodos , Neoplasias , Criopreservación/métodos , Medicina ReproductivaRESUMEN
RESUMEN La Insuficiencia Ovárica Primaria se define por una amenorrea secundaria de al menos cuatro meses de duración, deficiencia de esteroides sexuales (estradiol) y altas concentraciones séricas de hormona folículoestimulante (FSH) con al menos un mes de diferencia entre estas determinaciones, en mujeres menores de 40 años. Es una causa insidiosa de infertilidad pero en algunas ocasiones es transitoria y permite una gestación espontánea. El Síndrome de Turner es un trastorno genético caracterizado por la pérdida o anomalías estructurales de un cromosoma X y que afecta a 1 de cada 2.500 mujeres nacidas vivas. Las manifestaciones clínicas varían entre pacientes, pero generalmente se relaciona con talla baja, coartación aórtica, disgenesia gonadal e insuficiencia ovárica primaria. Las técnicas de reproducción asistida como la criopreservación de ovocitos y de tejido ovárico, la maduración in vitro o la donación de ovocitos ofrecen opciones reproductivas en aquellos casos en los que no se produzca un embarazo espontáneo.
ABSTRACT Primary Ovarian Insufficiency is considered a secondary amenorrhea of at least four months duration, sex steroid deficiency (estradiol) and high serum concentrations of follicle stimulating hormone (FSH) with at least one month difference between these determinations, in women under 40 years. It is an insidious cause of infertility but sometimes it is transient and allows a spontaneous pregnancy. Turner syndrome is a genetic disorder characterized by the loss or structural abnormalities of an X chromosome that affects 1 in 2,500 women born alive. Clinical manifestations vary among patients, but it is usually associated with short stature, aortic coarctation, gonadal dysgenesis, and primary ovarian failure. Assisted reproduction techniques such as cryopreservation of oocytes and ovarian tissue, in vitro maturation or oocyte donation offer reproductive options in those cases in which there is no spontaneous pregnancy.
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Síndrome de Turner/etiología , Insuficiencia Ovárica Primaria/etiología , Síndrome de Turner/diagnóstico , Síndrome de Turner/terapia , Técnicas Reproductivas , Fertilidad , Preservación de la Fertilidad/métodosRESUMEN
Actualmente, la necesidad de iniciar terapias antineoplásicas, no debe suponer la renuncia a la maternidad por parte de una paciente, que aún no haya completado sus deseos genésicos. Durante los últimos años, los avances socioeconómicos en los países desarrollados, han producido un retraso en la edad en las que las mujeres inician la búsqueda de su primera gestación. El objetivo del trabajo es mostrar una revisión pormenorizada de la literatura científica referente a la quimioprofilaxis con análogos de la GnRH, criopreservación de tejido ovárico y técnicas de estimulación ovárica para criopreservación de ovocitos y/o embriones, en pacientes con patología oncológica, sin deseos genésicos cumplidos. Se ha realizado una revisión bibliográfica de la literatura publicada en las bases de datos de PubMed, MedLine, Embase, BioMed Central y SciELO. Gracias a la mejoría de los tratamientos oncológicos, a los programas de detección precoz y a la aparición de nuevos fármacos y pautas terapéuticas, se ha incrementado la supervivencia de las pacientes con patologías oncológicas. Todo ello ha permitido el desarrollo de terapias genésicas óptimas, para este grupo de mujeres. La valoración inicial de estas pacientes debe incluir el grado de afectación de la función ovárica que les ocasionará el tratamiento y su repercusión en la reserva ovárica. La reserva ovárica es la cantidad de ovocitos que tiene la mujer en el momento del diagnóstico, ésta disminuye exponencialmente con la edad, por lo que es un factor muy importante a tener en cuenta.
Currently, the need to initiate antineoplastic therapies should not mean giving up on motherhood by a patient who has not yet fulfilled her desire to become a mother. In recent years, socioeconomic advances in developed countries have led to a delay in the age at which women begin their search for their first pregnancy. The objective of this paper is to show a detailed review of the scientific literature regarding chemoprophylaxis with GnRH analogues, cryopreservation of ovarian tissue and ovarian stimulation techniques for cryopreservation of oocytes and / or embryos, in patients with oncological pathology, who has not fulfilled their reproductive desires. A literature review was carried out in PubMed, MedLine, Embase, BioMed Central and SciELO databases. Thanks to the improvement of oncological treatments, early detection programs and the appearance of new drugs and therapeutic guidelines, the survival of patients with oncological pathologies has increased. All this has allowed the development of optimal gene therapy for this group of women. The initial assessment of these patients should include the degree of ovarian function impairment that will cause the treatment and its impact on the ovarian reserve. The ovarian reserve is the number of oocytes that the woman has at the time of diagnosis, this decreases exponentially with age, which is a very important factor to take into account.
Asunto(s)
Humanos , Femenino , Embarazo , Preservación de la Fertilidad/métodos , Reserva Ovárica/ética , Neoplasias/complicaciones , Complicaciones del Embarazo/epidemiología , Estudios ProspectivosRESUMEN
A oncofertilidade é um campo de interesse interdisciplinar de desenvolvimento recente que busca mesclar os conhecimentos em oncologia e medicina reprodutiva, com a contribuição das técnicas de reprodução assistida, para o desenvolvimento de estratégias de preservação da função gonadal e oferecer a possibilidade da procriação biológica aos sobreviventes de câncer. As estratégias de preservação da fertilidade feminina em pacientes oncológicas atualmente aceitas para a prática rotineira são a criopreservação de embriões e a criopreservação de oócitos maduros. Ocorre que, para execução de ambos, a indução de ovulação é obrigatória e, com ela, vêm os riscos teóricos de estimulação do crescimento de tumores estrogêniodependentes e a postergação do início do tratamento antineoplásico. Os protocolos de estimulação ovariana de início aleatório contemplam a intenção de se minimizar o atraso no início da quimioterapia ou radioterapia e o bloqueio ao crescimento tumoral e oferecem resultados satisfatórios, semelhantes aos obtidos em protocolos de início habitual. Apresentamos neste artigo as diretrizes clínicas da Sociedade Brasileira de Reprodução Humana para indução de ovulação em pacientes com tumor estrogêniodependente.(AU)
Oncofertility is an interdisciplinary interest field of recent development, which aims to merge the knowledge in oncology and reproductive medicine, with the help of assisted reproductive technologies, to develop strategies for gonadal function preservation and to offer the possibility of biological procreation to cancer survivors. Preservation strategies of female fertility in oncological patients currently accepted for routine practice are the cryopreservation of embryos and cryopreservation of mature oocytes. It happens that ovulation induction is mandatory for executing both strategies, and with it the theoretical risk of stimulation of estrogendependent tumors growth and the postponement of antineoplastic treatment. Randomstart ovarian stimulation protocols include the intention of minimizing the delay in onset of chemoradiotherapy and to block tumor growth, providing satisfactory results, similar to those obtained in the usual beginning protocols. This article presents the clinical guidelines of the Brazilian Society of Human Reproduction for ovulation induction in patients with estrogendependent tumors.(AU)
Asunto(s)
Humanos , Femenino , Preservación de la Fertilidad/métodos , Fertilización In Vitro/métodos , Neoplasias/complicaciones , Inducción de la Ovulación/métodosRESUMEN
Objective: This study was designed to evaluate the effects of vitrification and in vitro culture of human ovarian tissue on the expression of oocytic and follicular cell-related genes
Materials and Methods: In this experimental study, ovarian tissue samples were obtained from eight transsexual women. Samples were cut into small fragments and were then assigned to vitrified and non-vitrified groups. In each group, some tissue fragments were divided into un-cultured and cultured [in alpha-MEM medium for 2 weeks] subgroups. The normality of follicles was assessed by morphological observation under a light microscope using hematoxylin and eosin [H and E] staining. Expression levels of factor in the germ line alpha [FIGLA], KIT ligand [KL], growth differentiation factor 9 [GDF-9] and follicle stimulating hormone receptor [FSHR] genes were quantified in both groups by real-time reverse transcriptase polymerase chain reaction [RT-PCR] at the beginning and the end of culture
Results: The percentage of normal follicles was similar between non-cultured vitrified and non-vitrified groups [P>0.05], however, cultured tissues had significantly fewer normal follicles than non-cultured tissues in both vitrified and non-vitrified groups [P<0.05]. In both cultured groups the rate of primary and secondary follicles was significantly higher than non-cultured tissues [P<0.05]. The expression of all examined genes was not significantly altered in both non-cultured groups. Whiles, in comparison with cultured tissues non-cultured tissues, the expression of FIGLA gene was significantly decreased, KL gene was not changed, GDF-9 and FSHR genes was significantly increased [P<0.05]
Conclusion: Human ovarian vitrification following in vitro culture has no impairing effects on follicle normality and development and expression of related-genes. However, in vitro culture condition has deleterious effects on normality of follicles
Asunto(s)
Humanos , Mujeres , Adulto Joven , Adulto , Regulación de la Expresión Génica , Factor de Células Madre/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Receptores de HFE/genética , Preservación de la Fertilidad/métodos , Técnicas de Cultivo de TejidosRESUMEN
As the number of young cancer survivors increases, quality of life after cancer treatment is becoming an ever more important consideration. According to a report from the American Cancer Society, approximately 810,170 women were diagnosed with cancer in 2015 in the United States. Among female cancer survivors, 1 in 250 are of reproductive age. Anticancer therapies can result in infertility or sterility and can have long-term negative effects on bone health, cardiovascular health as a result of reproductive endocrine function. Fertility preservation has been identified by many young patients diagnosed with cancer as second only to survival in terms of importance. The development of fertility preservation technologies aims to help patients diagnosed with cancer to preserve or protect their fertility prior to exposure to chemo- or radiation therapy, thus improving their chances of having a family and enhancing their quality of life as a cancer survivor. Currently, sperm, egg, and embryo banking are standard of care for preserving fertility for reproductive-age cancer patients; ovarian tissue cryopreservation is still considered experimental. Adoption and surrogate may also need to be considered. All patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available in a timely manner, whether or not they decide to ultimately pursue fertility preservation. Because of the ever expanding number of options for treating cancer and preserving fertility, there is now an opportunity to take a precision medicine approach to informing patients about the fertility risks associated with their cancer treatment and the fertility preservation options that are available to them.
Asunto(s)
Femenino , Humanos , Células Madre Adultas , Técnicas de Cultivo de Célula , Criopreservación/métodos , Embrión de Mamíferos , Preservación de la Fertilidad/métodos , Neoplasias/tratamiento farmacológico , Oocitos , Folículo Ovárico/efectos de los fármacos , Ovario/trasplante , Inducción de la Ovulación/métodos , Medicina de PrecisiónRESUMEN
This study reports a case of a gonadotropin-releasing hormone agonist trigger in a young female with myelodysplastic syndrome (MDS) who underwent fertility preservation using random-start controlled ovarian stimulation. This method involves the stimulation of the ovary regardless of a patient's menstrual-cycle phase. A review of the related literature is also provided. A 17-year-old patient was diagnosed with MDS and required initiation of peripheral blood stem cell transplantation within a maximum of 3 weeks and was in the luteal phase of the menstrual cycle when the possibility of attempting preservation of fertility was presented to her. She opted for a random-start controlled ovarian stimulation with gonadotropins. With successful hemorrhagic prophylaxis, 17 oocytes were retrieved including 10 mature and 7 immature oocytes. Of the immature oocytes, 3 were successfully matured in vitro and a vitrification protocol was used to freeze the 13 mature oocytes.
Asunto(s)
Humanos , Femenino , Adolescente , Preservación de la Fertilidad/métodos , Síndromes Mielodisplásicos/fisiopatología , Inducción de la Ovulación/métodos , Criopreservación/métodos , Ciclo Menstrual/fisiología , Recuperación del Oocito/métodos , Oocitos/fisiología , Reproducibilidad de los Resultados , Resultado del TratamientoRESUMEN
ABSTRACT Spermatogonial stem cells, which exist in the testicles since birth, are progenitors cells of male gametes. These cells are critical for the process of spermatogenesis, and not able to produce mature sperm cells before puberty due to their dependency of hormonal stimuli. This characteristic of the reproductive system limits the preservation of fertility only to males who are able to produce an ejaculate. This fact puts some light on the increase in survival rates of childhood cancer over the past decades because of improvements in the diagnosis and effective treatment in pediatric cancer patients. Therefore, we highlight one of the most important challenges concerning male fertility preservation that is the toxic effect of cancer therapy on reproductive function, especially the spermatogenesis. Currently, the experimental alternative for fertility preservation of prepubertal boys is the testicular tissue cryopreservationfor, for future isolation and spermatogonial stem cells transplantation, in order to restore the spermatogenesis. We present a brief review on isolation, characterization and culture conditions for the in vitro proliferation of spermatogonial stem cells, as well as the future perspectives as an alternative for fertility preservation in prepubertal boys. The possibility of restoring male fertility constitutes a research tool with an huge potential in basic and applied science. The development of these techniques may be a hope for the future of fertility preservation in cases that no other options exist, e.g, pediatric cancer patients.
RESUMO As espermatogônias-tronco, presentes nos testículos desde o nascimento, são as células progenitoras dos gametas masculinos, e, desse modo, críticas para o processo de espermatogênese. Antes da puberdade, essas células não são capazes de produzir espermatozoides maduros, o que só ocorrerá após o estímulo hormonal. Essa característica do sistema reprodutivo limita a possibilidade de preservação da fertilidade apenas para homens capazes de produzir um ejaculado. Tal fato coloca em evidência o aumento nas taxas de sobrevivência de crianças com câncer nas últimas décadas, devido principalmente à melhora no diagnóstico e ao tratamento dos pacientes pediátricos. Dessa forma, destaca-se um dos mais importantes desafios relativos à preservação da fertilidade masculina, que é o efeito tóxico das terapias anticâncer para o sistema reprodutivo, especialmente a espermatogênese. Tendo isso em vista, a alternativa experimental atualmente estudada para a preservação da fertilidade de pacientes pré-púberes é a criopreservação de tecido testicular para futuro isolamento e transplante de espermatogônias-tronco, a fim de restabelecer a espermatogênese. Apresentamos aqui uma breve revisão sobre isolamento, caracterização e condições de cultivo para a proliferação de espermatogônias-tronco, bem como as futuras perspectivas, como alternativa para preservação da fertilidade de meninos pré-púberes. A possibilidade de restabelecer a fertilidade masculina é uma ferramenta de pesquisa com potencial enorme de uso na pesquisa básica e aplicada. O desenvolvimento dessas técnicas pode fornecer uma esperança futura de preservação de fertilidade nos casos em que não há nenhuma outra opção, como para os pacientes pediátricos de câncer.
Asunto(s)
Niño , Humanos , Masculino , Células Madre Adultas/trasplante , Preservación de la Fertilidad/métodos , Infertilidad Masculina/terapia , Trasplante de Células Madre , Biomarcadores , Criopreservación/métodos , Pubertad , Cultivo Primario de Células/métodos , Trasplante de Células Madre/tendenciasRESUMEN
Oncofertility is an emerging fi eld, merging oncology and reproductive endocrinology. Any woman facing a cancer diagnosis is devastated especially if she is young. Young women diagnosed with cancer face an additional burden of compromise of future fertility. Oncofertility aims to explore and expand fertility options to address reproductive concerns of young women with cancer diagnosis. Th is review aims to highlight the available and emerging options for young women diagnosed with gynecological cancers to enable them to realize their dream of parenthood.
Asunto(s)
Adulto , Femenino , Preservación de la Fertilidad/métodos , Humanos , Infertilidad/prevención & control , Masculino , Neoplasias/complicaciones , Neoplasias/diagnóstico , Responsabilidad Parental , ReproducciónRESUMEN
The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.
Asunto(s)
Femenino , Humanos , Preservación de la Fertilidad/métodos , Neoplasias de los Genitales Femeninos/terapia , Neoplasias Ováricas/terapia , Investigación Biomédica Traslacional/métodos , Neoplasias del Cuello Uterino/terapiaRESUMEN
No abstract available.
Asunto(s)
Femenino , Humanos , Preservación de la Fertilidad/métodos , Estadificación de Neoplasias , Neoplasias Ováricas/cirugíaRESUMEN
No abstract available.
Asunto(s)
Femenino , Humanos , Preservación de la Fertilidad/métodos , Neoplasias Ováricas/cirugíaRESUMEN
This study aimed to evaluate the efficacy of random-start controlled ovarian stimulation (COS) in cancer patients for emergency fertility preservation. In this retrospective comparative study, 22 patients diagnosed with cancer and 44 infertile women undergoing conventional in vitro fertilization (IVF) were included. In cancer patients, ovarian stimulation was started on the day of referral, irrespective of their menstrual cycle date. The control group was selected by age matching among women undergoing conventional IVF. COS outcomes were compared between groups. The number of total and mature oocytes retrieved and the oocyte maturity rate were higher in the random-start group than in the conventional-start group. However, duration of ovarian stimulation was longer in the random-start group (11.4 vs. 10.3 days, P = 0.004). The addition of letrozole to lower the estradiol level during COS did not adversely affect total oocytes retrieved. However, oocyte maturity rate was lower in cycles with letrozole than in cycles without letrozole (71.6% vs. 58.2%, P = 0.019). Our study confirms the feasibility and effectiveness of random-start COS in cancer patients.